GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Minority Interest

Arovella Therapeutics (ASX:ALA) Minority Interest : A$0.00 Mil (As of Jun. 2024)


View and export this data going back to 2002. Start your Free Trial

What is Arovella Therapeutics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Arovella Therapeutics's minority interest for the quarter that ended in Jun. 2024 was A$0.00 Mil.

Arovella Therapeutics Minority Interest Historical Data

The historical data trend for Arovella Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arovella Therapeutics Minority Interest Chart

Arovella Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arovella Therapeutics Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Arovella Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Arovella Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (ASX:ALA) » Definitions » Minority Interest
Comparable Companies
ASX:DXB ASX:LTP ASX:RAC ASX:OCC ASX:EZZ ASX:PAR ASX:IMU ASX:RCE ASX:NUZ ASX:AGN VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
E4NA:Germany
Address
84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Website
https://www.arovella.com
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

Arovella Therapeutics Headlines

No Headlines